Global private equity and venture capital news and research

Gimv leads €34m Series B investment in preclinical biotech developer Covagen

10 Dec 2013

Belgium-based investment firm Gimv has led a €34m tranched Series B financing round for preclinical-stage biotech company Covagen, one of the largest private financing rounds of its kind.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016